PROJECT

Projects

Environmental & Social Review Summary

Project Number

39247

Company Name

NOBEL ILAC SANAYII VE TICARET A.S.

Date ESRS Disclosed

Mar 21, 2017

Country

Turkiye

Region

Central Asia and Turkiye

Last Updated Date

Nov 2, 2017

Environmental Category

B - Limited

Status

Active

Previous Events

Approved : Jul 27, 2017
Signed : Jul 31, 2017
Invested : Oct 31, 2017

Sector

Pharmaceuticals and Medicine

Industry

Health, Education and Life Sciences

Department

Regional Industry - MAS ECA

Project Description

Turkey-based Nobel Ilac (“Nobel” or “the company” - http://www.nobel.com.tr)  is a leading pharmaceutical manufacturer and distributor of over 100 principal pharmaceutical products (tablets, injection etc.) and food supplement products. The company is part of the “Ulkar Holding Group”, (“Ulkar Group” or the “Group”) - a vertically-integrated group of pharmaceutical manufacturing, marketing and sales companies operating in 20 countries worldwide.

 The proposed investment includes USD 25 million A loan to Nobel for the expansion of its biotechnology business. Nobel’s capex plans include: (i) construction of a biotechnology and an injectable plant together with establishment of research and development laboratories (ii) and an automated warehouse (the “project”).

 The company will establish its biotechnology business in Duzce, about 200 km from Istanbul, within the same property where the existing plant is located.  The plant area in Duzce has been occupied by the company since 1999 after the takeover of the Turkish company Plantafarma. The plant is located in the city center and the nearest residential communities are located about 500 meter from the facility.

 The project will be housed in new 2-story purpose-built facility with a footprint of 8,000 m2 and a total floor space on 42,000 m2. Construction for this new greenfield development started in 2017 and will be concluded by 2020.

Overview of IFC's Scope of Review

IFC’s environmental and social (E&S) review of this investment consisted of appraising technical, environmental, health and safety (EHS) and social related information provided by the company, including: business details, corporate policies and procedures on EHS, management system documentation, regulatory permits, Human Resources (HR) policies and records, organization charts, environmental monitoring reports, safety audit reports, on-site/off-site emergency response plans, and other EHS related studies completed for the operating facilities.

 
The IFC team visited the company’s two manufacturing facilities between January 30thand February 14th2017 : (i) the final dosage plant in Duzce where the greenfield project will be developed, and (ii) “Ulkar Kimya”, an active pharmaceutical ingredients (API) manufacturing plant located in Tekirdag about 150 km to the west of Istanbul, which is one of the main API suppliers to Nobel. The appraisal also included discussions with the company’s senior management at its corporate headquarters in Istanbul and focused on current operations and plans for future biotechnology development as well as the technical and operational teams at the facilities visited.

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement

Broad Community Support

Environmental & Social Action Plan